Creso just locked in a New Zealand distribution deal for its CBD products
Health & Biotech
Link copied to
Special Report: Barely a day is going by without positive news out of medicinal cannabis innovator Creso Pharma, with the company signing an exclusive distribution deal for its CBD products in New Zealand.
Creso (ASX:CPH) is flexing its muscles ahead of its acquisition by large listed Canadian cannabis company PharmaCielo, with the new Kiwi deal following hot on the heels of an Australian distribution deal.
Today’s news sees Creso signing a comprehensive, exclusive distribution agreement with New Zealand partner Medleaf, which will sell Creso’s cannaQIX®50 therapeutic lozenges and its CBD Oils.
The two companies first agreed to work together back in January, on the back of New Zealand’s new cannabis laws. Medleaf has also placed a second order for cannaQIX®50 as it builds it patient base in New Zealand.
“The evolving regulatory situation in New Zealand is providing a solid foundation on which to build this close relationship with MedLeaf,” said Dr Miri Halperin Wernli, CEO and co-founder of Creso.
“We’re pleased with our progress to date and encouraged to see a wide range of new opportunities opening up to bring life-improving products to patients in New Zealand.”
Courtney Letica, CEO and founder of Medleaf, said the tie-up with Creso was particularly synergistic given Creso’s relationship with PharmaCielo.
“After three years of patient advocacy, Medleaf Therapeutics is proud to leverage this great relationship with Creso Pharma to bring greater choice to New Zealanders,” Letica said.
“With the environmentally sustainable, outdoor sun-grown crops from PharmaCielo and great product development of Creso Pharma, this partnership will see an opportunity for New Zealanders to gain access to affordable, highest quality, broad spectrum, GMP products.
“Our ultimate aim is to develop a world class, New Zealand-based cannabis business with leading research and development, cultivation, extraction and product development capabilities.”
This story was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing.
This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.